^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ukrain (NSC B238865)

    i
    Other names: UKSR 222, W122, NSC 631570, NSC B238865
    Associations

    News

    Trials
    Company:
    Nowicky
    Drug class:
    Tubulin polymerization inhibitor
    Related drugs:
    Associations

    News

    Trials
    over4years
    Anticancer effects of NSC‑631570 (Ukrain) in head and neck cancer cells: In vitro analysis of growth, invasion, angiogenesis and gene expression. (PubMed, Oncol Rep)
    Moreover, NSC‑631570 suppressed the growth of all tested HNSCC cell lines, including a paclitaxel‑resistant and P‑glycoprotein (MDR1)‑overexpressing cell line. In addition, NSC‑631570 showed a high anti‑angiogenic action on the tube formation ability of human umbilical vein endothelial cells (HUVECs). In conclusion, this study highlights NSC‑631570 as a promising therapeutic approach for HNSCC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1)
    |
    paclitaxel • Ukrain (NSC B238865)